Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + 5-fluorouracil + cisplatin
- Development stage
- Phase 1
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, developed by Shanghai Junshi Biosciences. In a clinical trial context led by Ruijin Hospital, it is being investigated as an induction therapy in combination with a chemotherapy regimen consisting of 5-fluorouracil and cisplatin (or carboplatin) for patients with locoregionally-advanced laryngo-hypopharyngeal squamous cell carcinoma. The mechanism of action involves toripalimab blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2) to restore anti-tumor T-cell activity, while the chemotherapy components provide cytotoxic effects by inhibiting DNA synthesis and inducing DNA damage. This combination approach is intended to reduce tumor burden and improve organ preservation rates in patients with locally advanced laryngeal and hypopharyngeal cancers.
- Brand names
- Tuoyi
- Other names
- toripalimab-tpgnFP combined with Toripalimab
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on toripalimab + 5-fluorouracil + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + 5-fluorouracil + cisplatin.